|
AU594014B2
(en)
|
1984-03-21 |
1990-03-01 |
Research Corporation Technologies, Inc. |
Recombinant DNA molecules
|
|
CA1282721C
(en)
|
1984-06-04 |
1991-04-09 |
Bernard Roizman |
Herpes simplex virus as a vector
|
|
US5288641A
(en)
|
1984-06-04 |
1994-02-22 |
Arch Development Corporation |
Herpes Simplex virus as a vector
|
|
EP0173552B1
(en)
|
1984-08-24 |
1991-10-09 |
The Upjohn Company |
Recombinant dna compounds and the expression of polypeptides such as tpa
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US5698531A
(en)
|
1989-03-31 |
1997-12-16 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US5328688A
(en)
|
1990-09-10 |
1994-07-12 |
Arch Development Corporation |
Recombinant herpes simplex viruses vaccines and methods
|
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
|
US6040169A
(en)
|
1991-01-31 |
2000-03-21 |
Medical Research Council |
Herpes simplex virus-1 deletion variants and vaccines thereof
|
|
JP3974167B2
(ja)
|
1992-03-31 |
2007-09-12 |
アーチ デベロプメント コーポレイション |
遺伝子，腫瘍及びウイルス感染の治療，並びにプログラムされた細胞死（アポプトーシス）を予防するための方法及び組成物
|
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
JPH11513390A
(ja)
|
1995-10-06 |
1999-11-16 |
アーチ デベロップメント コーポレイション |
細胞殺傷のウイルス増強のための方法および組成物
|
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
|
GB9700411D0
(en)
*
|
1997-01-10 |
1997-02-26 |
Univ London |
Eukaryotic gene expression cassette and uses thereof
|
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
BR0015491A
(pt)
|
1999-11-12 |
2002-10-15 |
Oncolytics Biotech Inc |
Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
|
|
GB2375113B
(en)
|
2000-01-21 |
2004-10-20 |
Biovex Ltd |
A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
|
|
EP1381280B1
(en)
|
2001-03-27 |
2011-05-11 |
Catherex, Inc. |
Viral vectors and their use in therapeutic methods
|
|
GB0317511D0
(en)
|
2003-07-25 |
2003-08-27 |
Biovex Ltd |
Viral vectors
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
WO2006048749A1
(en)
|
2004-11-04 |
2006-05-11 |
Pfizer Products Inc. |
Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
|
|
ES2569409T3
(es)
|
2005-03-08 |
2016-05-10 |
Pfizer Products Inc. |
Composiciones de anticuerpo anti-CTLA-4
|
|
AU2006262021C1
(en)
|
2005-06-23 |
2012-05-10 |
The University Of Houston |
Use of mutant Herpes Simplex Virus-2 for cancer therapy
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
WO2007123737A2
(en)
|
2006-03-30 |
2007-11-01 |
University Of California |
Methods and compositions for localized secretion of anti-ctla-4 antibodies
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
RU2573912C2
(ru)
|
2008-10-08 |
2016-01-27 |
Интрексон Корпорейшн |
Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
EP2502078A1
(en)
|
2009-11-20 |
2012-09-26 |
Infinity Pharmaceuticals, Inc. |
Methods and compositions for treating hedgehog-associated cancers
|
|
WO2011119925A2
(en)
|
2010-03-25 |
2011-09-29 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthetic herpes simplex viruses for treatment of cancers
|
|
WO2011118866A1
(ko)
|
2010-03-26 |
2011-09-29 |
연세대학교 산학협력단 |
네트워크를 통한 심사요청 방법
|
|
US20130243731A1
(en)
|
2010-09-24 |
2013-09-19 |
Oncos Therapeutics Oy |
Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
|
|
FI20115914L
(fi)
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
WO2013112942A1
(en)
|
2012-01-25 |
2013-08-01 |
Dna Trix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
|
AU2013296919A1
(en)
*
|
2012-07-30 |
2015-01-22 |
Alex Wah Hin Yeung |
Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
|
|
KR20210008155A
(ko)
|
2012-08-30 |
2021-01-20 |
암젠 인크 |
단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
|
|
EP2912063A1
(en)
|
2012-10-23 |
2015-09-02 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
|
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
|
EP2968525A4
(en)
|
2013-03-14 |
2016-10-26 |
Icahn School Med Mount Sinai |
MORBUS NEWCASTLE VIRUSES AND USES THEREOF
|
|
HUE042382T2
(hu)
|
2013-09-03 |
2019-06-28 |
Medimmune Ltd |
Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
|
|
HUE035875T2
(hu)
*
|
2013-10-25 |
2018-06-28 |
Psioxus Therapeutics Ltd |
Heterológ géneket tartalmazó onkolitikus adenovírusok
|
|
BR112016009465A8
(pt)
|
2013-10-28 |
2018-01-30 |
Univ Pittsburgh Commonwealth Sys Higher Education |
vetor de hsv oncolítico.
|
|
CN106029889A
(zh)
|
2013-11-22 |
2016-10-12 |
德那翠丝有限公司 |
表达免疫细胞刺激受体激动剂的腺病毒
|
|
WO2015128313A1
(en)
*
|
2014-02-25 |
2015-09-03 |
Deutsches Krebsforschungszentrum |
Rna viruses for immunovirotherapy
|
|
MA39818A
(fr)
|
2014-03-30 |
2017-02-08 |
Benevir Biopharm Inc |
Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
RU2696312C2
(ru)
*
|
2014-07-16 |
2019-08-01 |
Трансген Са |
Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
|
|
US20160040186A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Xiaoyun Liu |
Dna construct and method for transgene expression
|
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
WO2016118865A1
(en)
|
2015-01-23 |
2016-07-28 |
Dreamwell, Ltd. |
Automated mattress manufacturing process and apparatus
|
|
CN104987421A
(zh)
*
|
2015-05-13 |
2015-10-21 |
北京比洋生物技术有限公司 |
抗ctla-4和pd-1的双重可变结构域免疫球蛋白
|
|
US10612005B2
(en)
*
|
2016-01-08 |
2020-04-07 |
Replimune Limited |
Modified oncolytic virus
|
|
AU2016403583B2
(en)
*
|
2016-04-22 |
2020-05-28 |
Immvira Co., Limited |
Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
JP2021527694A
(ja)
*
|
2018-06-21 |
2021-10-14 |
レプリミュン リミテッド |
腫瘍溶解性ウイルスを用いた処置
|